Cervical prostaglandin injection: a novel method of administration for ripening the cervix and induction of labor

Intracervical prostaglandins for induction of labour

BACKGROUND

Prostaglandins have been used for cervical ripening and induction of labour since the 1970s. The goal of the administration of prostaglandins in the process of induction of labour is to achieve cervical ripening before the onset of contractions. One of the routes of administration that was proposed is intracervical. Using this route, prostaglandins are less easy to administer and the need for exposing the cervix may cause discomfort to the woman.

OBJECTIVES

To determine the effects of intracervical prostaglandins for third trimester cervical ripening or induction of labour compared with placebo/no treatment and with vaginal prostaglandins (except misoprostol).

SEARCH STRATEGY

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (August 2007) and bibliographies of relevant papers.

SELECTION CRITERIA

Clinical trials comparing intracervical prostaglandins used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods (vaginal prostaglandins, except misoprostol).

DATA COLLECTION AND ANALYSIS

A strategy was developed to deal with the large volume and complexity of trial data relating to labour induction. This involved a two-stage method of data extraction.

MAIN RESULTS

Fifty-six trials (7738 women) are included. INTRACERVICAL PGE2 WITH PLACEBO/NO TREATMENT: 28 TRIALS, 3764 WOMEN: Four studies reported the number of women who did not achieve vaginal delivery within 24 hours, showing a decreased risk with PGE2 (relative risk (RR) 0.61; 95% confidence interval (CI) 0.47 to 0.79). There was a small, and statistically non-significant, reduction of the risk of caesarean section when PGE2 was used (RR 0.88; 95% CI 0.77 to 1.00). The finding was statistically significant in a subgroup of women with intact membranes and unfavourable cervix only (RR 0.82; 95% CI 0.68 to 0.98). The risk of hyperstimulation with fetal heart rate (FHR) changes was not significantly increased (RR 1.21; 95% CI 0.72 to 2.05). However, the risk of hyperstimulation without FHR changes was significantly increased (RR 1.59; 95% CI 1.09 to 2.33. INTRACERVICAL PGE2 WITH INTRAVAGINAL PGE2: 29 TRIALS, 3881 WOMEN: The risk of not achieving vaginal delivery within 24 hours was increased with intracervical PGE2 (RR 1.26; 95% CI 1.12 to 1.41). There was no change in the risk of caesarean section (RR 1.07; 95% CI 0.93 to 1.22). The risks of hyperstimulation with FHR changes (RR 0.76; 95% CI 0.39 to 1.49) and without FHR changes (RR 0.80; 95% CI 0.56 to 1.15) were non-significantly different with the two methods of PGE2 administration. Only one trial with small sample size reported on women's views, with no difference between groups. INTRACERVICAL PGE2 LOW DOSE WITH INTRACERVICAL PGE2 HIGH DOSE: TWO TRIALS, 102 WOMEN: The trials are too small to provide any useful information.

AUTHORS' CONCLUSIONS

Intracervical prostaglandins are effective compared to placebo, but appear inferior when compared to intravaginal prostaglandins.

Natural Prostaglandins for Induction of Labor and Preinduction Cervical Ripening

Prostaglandin (PG) E2 has superseded all other natural prostaglandins for induction of labor and pre-induction cervical ripening. This evolution and its rationale are briefly described. PGE2 has been administered intravenously, orally, vaginally, endocervically, and extra-amniotically for induction of labor. All of these, except the intravenous route, have also been explored for pre-induction cervical ripening. The distinction between formal induction and pre-induction is not always clearly made with many studies pursuing both goals at once. Nevertheless, the effectiveness of PGE2 to achieve ripening and induction is currently beyond doubt. In women with unfavorable induction prospects PGE2 results in lower rates of failed induction and higher rates of delivery within a reasonable interval than amniotomy and/or oxytocin. This also applies to women with prelabor rupture of the membranes, but the relative advantages of PGE2 over traditional methods are less clear for women with a favorable cervix. Vaginal administration of PGE2 has superseded virtually all other routes of PGE2 administration except the endocervical route, which tends to give variable results depending on spillage from the endocervical canal. Doses and formulations of vaginal PGE2 with various gels, tablets, pessaries and slow release inserts have varied widely and continue to do so. There is currently no evidence for the superiority of one PGE2 preparation over another.